Statement by an American Association of Clinical Endocrinologists/ American College of Endocrinology Consensus Panel on Type 2 Diabetes Mellitus: An Algorithm for Glycemic Control

Rodbard, 2007, American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus [published correction appears in Endocr Pract. 2008;14:802-803], Endocr Pract, 13, 1, 10.4158/EP.13.S1.1

American Diabetes Association, 2009, Executive summary: standards of medical care in diabetes—2009, Diabetes Care, 32, S6

The Management of Diabetes Mellitus Working Group, 1999, VHA/DOD Clinical Practice Guideline for the Management of Diabetes Mellitus in the Primary Care Setting. Version 2.2. December

International Diabetes Federation, 2005 Clinical Guidelines Taskforce, 2009

Nathan, 2006, Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy; a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes, Diabetologia., 49, 1711, 10.1007/s00125-006-0316-2

Nathan, 2006, Diabetes Care., 29, 1963, 10.2337/dc06-9912

Nathan, 2009, Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy; a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes, Diabetes Care., 32, 193, 10.2337/dc08-9025

Woo, 2009, Important differences: Canadian Diabetes Association 2008 clinical practice guidelines and the consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes [with author reply], Diabetologia., 52, 552, 10.1007/s00125-008-1236-0

Woo, 2009, Diabetes Care., 32, e37

Jellinger, 2007, Road maps to achieve glycemic control in type 2 diabetes mellitus: ACE/ AACE Diabetes Road Map Task Force, Endocr Pract., 13, 260, 10.4158/EP.13.3.260

Inzucchi, 2008, Diabetes Facts and Guidelines 2008-2009: Type 2 DM Treatment Algorithms. New Haven, CT: Yale Diabetes Center, 66

Nathan, 2005, Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes, N Engl J Med., 353, 2643, 10.1056/NEJMoa052187

Holman, 2008, 10-year follow-up of intensive glucose control in type 2 diabetes, N Engl J Med, 359, 1577, 10.1056/NEJMoa0806470

Gaede, 2008, Cost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno-2 study, Diabetes Care., 31, 1510, 10.2337/dc07-2452

Miller, 2008, Effects of intensive glucose lowering in type 2 diabetes, N Engl J Med., 358, 2545, 10.1056/NEJMoa0802743

Patel, 2008, Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes, N Engl J Med., 358, 2560, 10.1056/NEJMoa0802987

Duckworth, 2009, Glucose control and vascular complications in veterans with type 2 diabetes [published correction appears in N Engl J Med. 2009;361:1024-1025, 1028], N Engl J Med., 360, 129, 10.1056/NEJMoa0808431

Home, 2009, Rosiglitazone Evaluated for Cardiovascular Outcomes in Oral Agent Combination Therapy for Type 2 Diabetes (RECORD): a multicentre, randomised, openlabel trial, Lancet, 373, 2125, 10.1016/S0140-6736(09)60953-3

Wilcox, 2008, Am Heart J., 155, 712, 10.1016/j.ahj.2007.11.029

Ray, 2009, Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials, Lancet., 373, 1765, 10.1016/S0140-6736(09)60697-8

Garg, 2006, Relationship of fasting and hourly blood glucose levels to HbA1c values: safety, accuracy, and improvements in glucose profiles obtained using a 7-day continuous glucose sensor, Diabetes Care., 29, 2644, 10.2337/dc06-1361

Dormuth, 2009, Thiazolidinediones and fractures in men and women, Arch Intern Med., 169, 1395, 10.1001/archinternmed.2009.214

Kahn, 2008, Rosiglitazone-associated fractures in type 2 diabetes: an analysis from A Diabetes Outcome Progression Trial (ADOPT), Diabetes Care., 31, 845, 10.2337/dc07-2270

Amiel, 2008, Hypoglycaemia in type 2 diabetes, Diabet Med., 25, 245, 10.1111/j.1464-5491.2007.02341.x

Adler, 2009, Antecedent hypoglycemia impairs autonomic cardiovascular function: implications for rigorous glycemic control, Diabetes., 58, 360, 10.2337/db08-1153

Cryer, 2008, Hypoglycemia: still the limiting factor in the glycemic management of diabetes, Endocr Pract., 14, 750, 10.4158/EP.14.6.750

Donnelly, 2005, Frequency and predictors of hypoglycaemia in type 1 and insulin-treated type 2 diabetes: a population-based study, Diabet Med, 22, 749, 10.1111/j.1464-5491.2005.01501.x

UK Hypoglycaemia Study Group, 2007, Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration, Diabetologia., 50, 1140, 10.1007/s00125-007-0599-y

Kelly, 2009, Systematic review: glucose control and cardiovascular disease in type 2 diabetes, Ann Intern Med., 151, 394, 10.7326/0003-4819-151-6-200909150-00137

Beaser, 2007

Cooper-DeHoff, 2009, Cardiovascular therapies and associated glucose homeostasis: implications across the dysglycemia continuum, J Am Coll Cardiol, 53, S28, 10.1016/j.jacc.2008.10.037

Juurlink, 2003, Drug-drug interactions among elderly patients hospitalized for drug toxicity, JAMA., 289, 1652, 10.1001/jama.289.13.1652

Mohr, 2005, A retrospective, comparative evaluation of dysglycemias in hospitalized patients receiving gatifloxacin, levofloxacin, ciprofloxacin, or ceftriaxone, Pharmacotherapy., 25, 1303, 10.1592/phco.2005.25.10.1303

Niemi, 2003, Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide, Diabetologia., 46, 347, 10.1007/s00125-003-1034-7

Somogyi, 1987, Reduction of metformin renal tubular secretion by cimetidine in man, Br J Clin Pharmacol., 23, 545, 10.1111/j.1365-2125.1987.tb03090.x

Baldwin, 1999, Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone, Br J Clin Pharmacol., 48, 424, 10.1046/j.1365-2125.1999.00030.x

Niemi, 2004, Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone, Clin Pharmacol Ther., 76, 239, 10.1016/j.clpt.2004.05.001

Ben-Ami, 1999, An interaction between digoxin and acarbose, Diabetes Care., 2, 860, 10.2337/diacare.22.5.860

Morreale, 1997, Probable interaction of warfarin and acarbose, Am J Health Syst Pharm., 54, 1551, 10.1093/ajhp/54.13.1551